110 related articles for article (PubMed ID: 2204443)
1. The possible role of electron-transfer complexes in the antitumour action of amsacrine analogues.
Baguley BC
Biophys Chem; 1990 Apr; 35(2-3):203-12. PubMed ID: 2204443
[TBL] [Abstract][Full Text] [Related]
2. Electron donor properties of the antitumour drug amsacrine as studied by fluorescence quenching of DNA-bound ethidium.
Davis LM; Harvey JD; Baguley BC
Chem Biol Interact; 1987; 62(1):45-58. PubMed ID: 3581286
[TBL] [Abstract][Full Text] [Related]
3. Quenching of DNA-ethidium fluorescence by amsacrine and other antitumor agents: a possible electron-transfer effect.
Baguley BC; Le Bret M
Biochemistry; 1984 Feb; 23(5):937-43. PubMed ID: 6546881
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo assessment of activity of new anilino-substituted analogues of amsacrine against Lewis lung carcinoma.
Rewcastle GW; Denny WA; Wilson WR; Baguley BC
Anticancer Drug Des; 1986 Nov; 1(3):215-22. PubMed ID: 3450294
[TBL] [Abstract][Full Text] [Related]
5. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
[TBL] [Abstract][Full Text] [Related]
6. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
8. Amsacrine analogues with extended chromophores: DNA binding and anti-tumour activity.
Denny WA; Baguley BC
Anticancer Drug Des; 1987 Aug; 2(1):61-70. PubMed ID: 3449085
[TBL] [Abstract][Full Text] [Related]
9. [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus].
René B; Fossé P; Khélifa T; Jacquemin-Sablon A; Bailly C
Bull Cancer; 1997 Oct; 84(10):941-8. PubMed ID: 9435795
[TBL] [Abstract][Full Text] [Related]
10. A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine.
Baguley BC; Leteurtre F; Riou JF; Finlay GJ; Pommier Y
Eur J Cancer; 1997 Feb; 33(2):272-9. PubMed ID: 9135499
[TBL] [Abstract][Full Text] [Related]
11. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
Finlay GJ; Riou JF; Baguley BC
Eur J Cancer; 1996 Apr; 32A(4):708-14. PubMed ID: 8695277
[TBL] [Abstract][Full Text] [Related]
12. Induction of petite formation in Saccharomyces cerevisiae by experimental antitumour agents. Structure--activity relationships for 9-anilinoacridines.
Ferguson LR; Baguley BC
Mutat Res; 1981 Dec; 90(4):411-23. PubMed ID: 7038462
[TBL] [Abstract][Full Text] [Related]
13. Steric constraints for DNA binding and biological activity in the amsacrine series.
Denny WA; Twigden SJ; Baguley BC
Anticancer Drug Des; 1986 Apr; 1(2):125-32. PubMed ID: 3450288
[TBL] [Abstract][Full Text] [Related]
14. Kinetic and equilibrium studies of the interaction of amsacrine and anilino ring-substituted analogues with DNA.
Denny WA; Wakelin LP
Cancer Res; 1986 Apr; 46(4 Pt 1):1717-21. PubMed ID: 3753896
[TBL] [Abstract][Full Text] [Related]
15. [Quenching of ethidium-DNA fluorescence by novel acridines with antitumor activities. II. The structure-activity relationship in acridines with fluorescence quenching of ethidium-DNA].
Kimura M; Inoue H; Uchitubo T; Kojima H; Okabayashi I
Yakugaku Zasshi; 1993 Jun; 113(6):454-9. PubMed ID: 8355147
[TBL] [Abstract][Full Text] [Related]
16. [Quenching of ethidium-DNA fluorescence by novel acridines with antitumor activities].
Kimura M
Yakugaku Zasshi; 1992 Dec; 112(12):914-8. PubMed ID: 1294716
[TBL] [Abstract][Full Text] [Related]
17. Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.
Baguley BC; Holdaway KM; Fray LM
J Natl Cancer Inst; 1990 Mar; 82(5):398-402. PubMed ID: 2154584
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress?
Baguley BC; Wakelin LP; Jacintho JD; Kovacic P
Curr Med Chem; 2003 Dec; 10(24):2643-9. PubMed ID: 14529454
[TBL] [Abstract][Full Text] [Related]
19. 'Minimal' DNA-intercalating agents as anti-tumour drugs: 2-styrylquinoline analogues of amsacrine.
Denny WA; Atwell GJ; Baguley BC
Anticancer Drug Des; 1987 Dec; 2(3):263-70. PubMed ID: 3449090
[TBL] [Abstract][Full Text] [Related]
20. Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of amsacrine.
Baguley BC; Wilson WR
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):607-13. PubMed ID: 3653185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
